Clinical Trials

Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

• Short Title MS700568_0183 MyClad
• Category Neurology
• Status Recruiting

Participating Locations

Erlanger

Principal Investigator

Chelsea Shugars, MD

Contact

• Name Erlanger Institute for Clinical Research
• Phone 4237783900
• Email [email protected]